(MDVN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 09/29/2016)
Today's Range
50-Day Range N/A
52-Week Range
Average Volume3.55 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive MDVN News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

(MDVN) logo

About (MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

(MDVN) (NASDAQ:MDVN) Frequently Asked Questions

What stocks does MarketBeat like better than (MDVN)?

Wall Street analysts have given (MDVN) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but (MDVN) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were (MDVN)'s earnings last quarter?

(MDVN) (NASDAQ:MDVN) issued its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to the consensus estimate of $214.52 million. (MDVN)'s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.58 earnings per share.
View (MDVN)'s earnings history

Who are some of (MDVN)'s key competitors?

What other stocks do shareholders of (MDVN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is (MDVN)'s stock symbol?

(MDVN) trades on the NASDAQ under the ticker symbol "MDVN."

What is (MDVN)'s stock price today?

One share of MDVN stock can currently be purchased for approximately $81.44.

What is (MDVN)'s official website?

The official website for (MDVN) is

Where are (MDVN)'s headquarters?

(MDVN) is headquartered at 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States.

How can I contact (MDVN)?

(MDVN)'s mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470.

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.